Cardiopulmonary bypass and activation of antithrombotic plasma protein C  by Petäjä, Jari et al.
422
postischemic recovery, and it may be related to periop-
erative myocardial infarction.5-7 Thus the regulation of
coagulation and potential physiologic anticoagulant
defensive mechanisms during myocardial ischemia are
highly relevant for the pathophysiology of the coronary
artery disease and for the operative management of the
disease. 
Protein C pathway is a major physiologic anticoagu-
lant system whose defects result in significant throm-
botic diathesis.8-12 Activated protein C (APC) may be
an important anticoagulant in arterial circulation
because, in animal studies, both physiologic activation
of protein C in ischemic coronary circulation13 and
promising results of therapeutic use of APC in several
models of arterial thrombosis have been reported.14-19
During human cardiac surgery and coronary ischemia,
the protein C pathway has previously been evaluated in
terms of its nonenzymatic components, including
zymogen protein C,20,21 but informative data for APC
levels in plasma are lacking.
A cute thrombosis of coronary arteries is a centralevent in myocardial infarction,1-3 and microvessel
thrombi may exacerbate the ischemic damage.4
Activation of coagulation in the coronary vascular bed
during cardiac operations may also impair myocardial
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In this study, we demonstrate a significant activation
of protein C during cardiopulmonary bypass (CPB) and
especially during myocardial reperfusion. Moreover,
the increase in APC measured after 10 minutes of
reperfusion is associated with more favorable cardiac
function 24 hours after the operation. The data suggest
an antithrombotic role for protein C activation during
vascular ischemia. 
Patients and methods
Patients. We studied 20 men undergoing CPB for elective
coronary artery bypass grafting. The mean age was 61 years,
ranging from 42 to 77 years. The present study was integrat-
ed with an intervention trial of nitecapone during CPB.22
Seven of the patients belonged to the control group and 13 of
the patients to the nitecapone group (see below). 
Anesthesia and operation. Patients were premedicated
with lorazepam. Anesthesia was both induced and maintained
with fentanyl citrate and midazolam. Enflurane or isoflurane
was supplemented when needed. Pancuronium was used for
muscle relaxation. A ventilator was used before CPB and
after aortic unclamping. 
The aorta and right atrium were cannulated for CPB. Left
ventricular pressure was measured with a 4F pediatric ther-
modilution catheter (Arrow AI-07122, Arrow International,
Inc, Reading, Pa) and single-use transducer (Deltran II, Utah
Medical Products, Inc, Midvale, Utah). The catheter was
placed into the left ventricle via the right superior pulmonary
vein and the mitral valve. The coronary sinus was catheter-
ized through the right atrium with a 14F coronary sinus can-
nula (Research Medical Inc, Sandy, Utah).
With the aid of conventional monitor devices and tech-
niques, multiple hemodynamic variables (heart rate, stroke
volume, mean arterial pressure [MAP], cardiac output [CO]
and cardiac index [CO/body surface area], mean central
venous pressure [CVP], pulmonary capillary wedge pressure
[PCWP], mean pulmonary artery pressure [PAP], diastolic
PAP, systemic vascular resistance [SVR], systemic vascular
resistance index, pulmonary vascular resistance [PVR], and
pulmonary vascular resistance index) were recorded at induc-
tion, immediately after CPB, on closure of the sternum, and 6
and 24 hours after the operation. In the calculations, the fol-
lowing formulas were used:
SVR = 80 · (MAP – CVP)/CO
PVR = 80 · (PAP – PCWP)/CO
The extracorporeal circuit was primed with 2000 mL of
crystalloid solution containing 5000 IU of heparin. Before
cannulation, the patients received a 300 IU/kg dose of
heparin. Additional heparin was given when needed to main-
tain the activated clotting time over 400 seconds. CPB was
conducted with nonpulsatile perfusion at a flow rate of 2.0 to
2.4 L/m2. Mean arterial pressure was maintained at 40 to 80
mm Hg and hypothermia at 30°C to 32°C. The mean duration
of CPB was 95 minutes (range, 47-146 minutes). After cessa-
tion of CPB, protamine (1 mg/100 IU of heparin) was admin-
istered. The duration of the extracorporeal perfusion after
aortic unclamping was, on average, 30% of aortic cross-
clamping time. 
The present study was integrated as a part of a nitecapone
intervention trial. Nitecapone is a catechol derivative acting
as a scavenger of superoxide, nitric oxide, hydrogen perox-
ide, and hydroxyl radicals, resulting in an antioxidant effect.
In the control subjects, cardioplegia was induced with
Plegisol solution (Orion-Pharma, Espoo, Finland) in a dose
of 15 mL/kg body weight. An additional 2.0 mL/kg dose of
the cardioplegic solution was infused every 15 minutes unless
earlier necessitated by ventricular fibrillation. In the nite-
capone group, a 50 m mol/L concentration of nitecapone
(Orion-Pharma) was added to the cardioplegic solution. 
Blood samples. The timing of the blood samples was as
follows: after induction of anesthesia but before the operation
began (Pre), just before the onset of CPB (Before), just before
aortic unclamping (0), and at 1, 5, and 10 minutes after aor-
tic unclamping. After induction of anesthesia and just before
aortic unclamping, a blood sample was drawn from the radi-
al arterial cannula. At other time points, parallel blood sam-
ples were drawn from the aortic root and the coronary sinus.
Nine volumes of blood were mixed with 1 volume of 0.109
mol/L trisodium citrate or, for APC and fibrinopeptide A
(FPA) assays, with 1 volume of 0.2 mol/L EDTA + 0.3 mol/L
benzamidine in 10 mmol/L HEPES, pH 7.4. Platelet poor
plasma was separated by centrifugation (1900g for 15 min-
utes at 4°C) and the samples were stored at –70°C until
assayed. 
Laboratory methods. The assays were run as duplicates.
For all assays except for APC measurements, pooled normal
human plasma from Precision Biologicals (Dartmouth, Nova
Scotia, Canada) was used as a standard and the results are
expressed as percentage relative to this plasma pool defined
as 100%. For the APC assays, another, noncommercial plas-
ma pool was used as a standard and taken as 100%.23
APC levels in plasma were determined by an enzyme cap-
ture assay as described previously.23 In brief, a monoclonal
antibody against protein C was immobilized in microplates,
after which the surface was blocked. Then, plasma samples
containing APC and benzamidine, a reversible inhibitor of
APC, were incubated in the wells for capture of APC and pro-
tein C antigen. Then unbound sample constituents and the
benzamidine were removed by extensive washing. Finally, the
amidolytic activity of the captured APC was measured with a
chromogenic substrate S-2366 (Chromogenix AB, Mölndal,
Sweden). The sensitivity of this assay is 5 pmol/L, corre-
sponding to 13% of the normal mean plasma level.23 Total
protein C based on its activity was measured by activating the
bound protein C in the immunocaptured samples by Protac
reagent (American Diagnostica, Greenwich, Conn) and by
then measuring the amidolytic activity on the chromogenic
substrate S-2366.23 Since APC was less than 1% of total pro-
tein C, the amidolytic activity observed after Protac reagent
activation essentially equaled total protein C. Protein C anti-
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gen and total protein S antigen were assayed by Asserachrom
Protein C and Asserachrom Protein S kits from Diagnostica
Stago (Parsippany, NJ), respectively. Free protein S was deter-
mined by a sandwich enzyme-linked immunosorbent assay
method with 2 monoclonal anti–free protein S antibodies as
described earlier.24 C4b-binding protein was measured by an
enzyme-linked immunosorbent assay.24
FPA levels were measured from the plasma samples anti-
coagulated with EDTA-benzamidine with the use of an
Asserachrom FPA kit (American Diagnostics, Parsippany,
NJ). Fibrinogen was removed from the samples by centrifug-
ing sample aliquots in 0.5 mL spin vials fitted with 30,000
molecular weight cut off membranes (Gelman Sciences, Ann
Arbor, Mich).25
Statistical methods. Plasma concentrations of variables
were calculated both corrected and uncorrected for hemat-
ocrit value. Within CPB and reperfusion, hemodilution did
not have any significant effect on the results. Therefore the
A B
C D
Fig 1. Protein C and activated protein C (APC) plasma levels during CPB operations in 20 patients. A and B,
Plasma protein C zymogen levels assayed with a functional or antigenic measurement, respectively. C, Plasma
levels of APC. D, Calculated APC/protein C antigen ratios. The significance levels are for 2-tailed Wilcoxon
signed rank test when compared with the preoperative sample. *P < .05, **P < .01; ***P < .001. In time of sam-
pling, Pre indicates preoperative, Before indicates just before CPB, 0, just before aortic unclamping, and 1, 5, and
10 indicate minutes after aortic unclamping. Open symbols indicate arterial samples and closed symbols indicate
samples from the coronary sinus. The error bars indicate standard error of the mean. X-clamp indicates aortic
crossclamping time.
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results are presented as uncorrected. When values during the
operation were compared with those at induction, the 2-
tailed Wilcoxon signed rank test was used because large dif-
ferences in variances necessitated a nonparametric approach.
When variances were not significantly different, continuous
variables with normal distributions were also compared with
the Student t test for unpaired samples. The Spearman rank
correlation coefficient was used for calculation of correla-
tions. Data are presented as mean ± standard error of mean
(SEM). 
Ethics. The study was approved by the ethics committee of
the University Central Hospital of Helsinki and by the
Ministry of Health of Finland. Informed consent was
obtained from each patient before entry into the study.
Results
Protein C and APC data were initially analyzed sepa-
rately for the patients who received nitecapone (n = 13)
and for those who did not (n = 7). No significant dif-
ferences between APC and protein C for the 2 groups
were observed for any of the sampling times (data not
shown). Similarly, no significant differences were
observed between the nitecapone-treated or control
patients in any of the measured hemodynamic variables
from induction to the first postoperative day. Thus the
patient groups were combined for all subsequent analy-
ses presented below. 
Plasma levels of protein C activity and antigen and of
APC for the 20 subjects at various times before and
during CPB are shown in Fig 1, A to D. In 1 patient,
samples after aortic unclamping were not obtained and
all presented data involving post-unclamping samples
are for 19 subjects. Hemodilution during CPB resulted
in a 40% to 50% decrease in protein C levels (Fig 1, A
and B). In contrast, APC plasma levels decreased by
about 20% before CPB and remained stable despite the
hemodilution during the operation. Remarkably, during
reperfusion a rapid and pronounced increase in APC
levels occurred that was linear with time (Fig 1, C).
When the data were analyzed as the ratio between APC
and protein C antigen level, which is not affected by
hemodilution, the rate of APC increase was greatly
enhanced on reperfusion (Fig 1, D). Even though we
probably did not observe the true “APC peak” (APC
was still rising at the 10-minute sample), 79% of the
total measured increase in the APC/protein C ratio
occurred after aortic unclamping and only 21% of the
increase was measured during aortic crossclamping. A
comparison of venous and arterial samples showed no
gradient in the APC levels across the coronary vascular
bed (Fig 1, C and D). 
FPA levels increased in parallel with APC levels.
During early reperfusion, the FPA levels in sinus blood
tended to be higher than those in the aortic blood
although the difference was significant only for the sam-
ple drawn 5 minutes after reperfusion (P = .02) (Fig 2).
When all the samples were combined, APC and total
protein C antigen showed a moderate but statistically
highly significant positive correlation (Spearman R =
0.250, P = .0005). At individual time points, the
strongest correlation between APC and protein C was
observed just before CPB (“Before” samples)
(Spearman R = 0.800 and 0.637 for arterial and sinus
samples, respectively), which corresponds with the
phase of operation when the patient is stabilized and
not yet challenged by CPB. In contrast, during reperfu-
sion the significant correlation between APC and pro-
tein C antigen was lost, presumably because of protein
C activation. A significant positive correlation was
observed between FPA and APC levels (Spearman R =
0.487, P < .0001). In contrast to the loss of correlation
between APC and protein C, the correlation between
FPA and APC levels became stronger as the operation
proceeded and FPA levels increased (Fig 2). 
The levels of free protein S, total protein S, and C4b-
binding protein are shown in Table I. In accordance
with the presumed acute phase reaction of the current
patients with severe symptomatic coronary heart dis-
ease, the baseline levels of total C4b-binding protein
Fig 2. Fibrinopeptide A plasma levels in 20 patients. Open
symbols indicate arterial samples and closed symbols indicate
samples from the coronary sinus. Time of sampling is the
same as for Fig 1. The significance levels are for the 2-tailed
Wilcoxon signed rank test when compared with the preoper-
ative sample. *P < .05; **P < .01; ***P < .001. The difference
between coupled samples from the coronary sinus and aorta
was significant for the sample drawn 5 minutes after aortic
unclamping (P = .02). The error bars indicate standard error
of the mean. X-clamp indicates aortic crossclamping time.
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were about twice normal (209% ± 14% of normal).
Since protein S complexes with C4b-binding protein,24
it is logical that free protein S, which represents an
active anticoagulant cofactor for APC, was also
reduced in the preoperative sample (70% ± 4% of nor-
mal mean). The ratio of free to total protein S reflects
availability of protein S as an APC cofactor. As seen in
Table I, this ratio decreased from the preoperative 0.61
± 0.03 to 0.50 ± 0.03 just before CPB and later nor-
malized to 0.56 ± 0.05 toward the end of the observa-
tion period. However, when compared with alterations
in the APC level (Fig 1), the slight albeit statistically
significant drop in the free/total protein S ratio caused
only a minor change in the availability of free protein
S, an APC cofactor, during the operation and CPB. 
To test whether the APC formation that occurred dur-
ing reperfusion was related to the postoperative hemo-
dynamic recovery, we divided the patients into good
(GR, n = 11, nitecapone 7, placebo 4) and poor APC-
generation responders (PR, n = 8, nitecapone 5, place-
bo 3) on the basis of an arbitrary cutoff value of 1.50
for the APC/protein C antigen ratio in the sample
drawn from coronary sinus at 10 minutes after reperfu-
sion. This sampling site was chosen because it most
specifically represented the local APC level in the coro-
nary vascular bed, and the sampling time was chosen
because it presented the maximum APC generation
response. No significant differences were observed in
the preoperative ejection fraction, duration of CPB or
ischemia time, or number of vascular anastomoses
between the PR and GR groups (data not shown). At
induction, there were no differences in the multiple
recorded hemodynamic variables (see “Patients and
methods”). However, during the first 24 postoperative
hours, significant differences between the PR and GR
groups developed in cardiac index (at 6 hours, P = .13;
at 24 hours, P = .03), mean pulmonary artery pressure
(at 6 hours, P = .06; at 24 hours, P = .047), and sys-
temic vascular resistance index (at 6 hours, P = .53; at
24 hours, P = .02) (Fig 3, A, B, and C). At 24 hours,
central venous pressure tended to be higher in GR
group than in the PR group (12.8 ± 1.7 vs 8.4 ± 0.9 mm
Hg, P = .06, respectively). No significant difference
was detected in the level of free protein S between GR
and PR groups (data not shown). 
To test that the apparent difference in the hemody-
namic recovery of the GR and PR groups was not
dependent on the arbitrarily chosen cutoff value 1.5 for
the APC/protein C antigen ratio, we calculated direct
correlations between this ratio for the 10-minute reper-
fusion sample and the various hemodynamic variables
measured 24 hours after the operation. The Spearman
rank correlation coefficients (R) with associated signifi-
cance levels for different variables were as follows: car-
diac output, R = 0.394, P = .078; cardiac index, R =
0.292, P = .22; pulmonary artery pressure, R = 0.754, P
= .0008; systemic vascular resistance index, R = –0.448,
P = .045; central venous pressure, R = 0.596, P = .012.
Table I. Protein S and C4b-binding protein (C4BP) levels in 20 CPB patients
Sample Total protein S (%) Free protein S (%) Free/total protein S ratio C4BP (%)
Pre 117 ± 5 70 ± 4 0.61 ± 0.03 209 ± 14
Before (A) 115 ± 6 63 ± 4 0.55 ± 0.03 201 ± 14
(NS) (.04) (NS) (NS)
Before (S) 118 ± 7 57 ± 4 0.50 ± 0.03 187 ± 12
(NS) (.008) (.01) (.04)
0 min 84 ± 5 42 ± 3 0.52 ± 0.04 140 ± 7
(.0003) (.0001) (NS) (.0003)
1 min (A) 81 ± 3 42 ± 2 0.53 ± 0.04 133 ± 7
(.0001) (.0002) (.04) (.0002)
1 min (S) 81 ± 5 43 ± 2 0.55 ± 0.04 135 ± 9
(.0001) (.0002) (.03) (.001)
5 min (A) 84 ± 6 46 ± 3 0.57 ± 0.04 161 ± 14
(.0002) (.0002) (NS) (.004)
5 min (S) 86 ± 5 47 ± 3 0.57 ± 0.04 151 ± 12
(.0002) (.0002) (NS) (.0003)
10 min (A) 87 ± 5 46 ± 3 0.56 ± 0.04 142 ± 7
(.0007) (.0003) (NS) (.0015)
10 min (S) 85 ± 5 45 ± 3 0.56 ± 0.05 133 ± 6
(.0005) (.0007) (NS) (.001)
Total and free protein S, as well as C4BP, are expressed as percentage of normal mean values. The significance levels in parentheses are for 2-tailed Wilcoxon signed
rank test when the sample value was compared with the preoperative sample value. For timing of samples see “Patients and methods.” A, Samples drawn from aorta;
S, samples drawn from coronary sinus; NS, not significant. Means ± standard error of the mean are presented.
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Discussion 
The antithrombotic protein C pathway was activated
during cardiac surgery and especially during reperfu-
sion of ischemic cardiac and other vascular beds.
Moreover, low APC levels measured in coronary
venous blood after 10 minutes of reperfusion correlat-
ed with compromised myocardial and circulatory per-
formance 24 hours later. It was not possible to define in
which part of the circulation APC formation was most
enhanced. However, in rabbits, intravenously infused
thrombin is cleared mainly by lungs in a first-pass fash-
ion,26 probably because of large quantities of endothe-
lial thrombomodulin, the membrane protein required
for protein C activation by thrombin.27 Another alter-
native is the hypoperfused splanchnic bed that may also
be “reperfused” when the nonpulsatile flow by the
pump is gradually turned into the pulsatile pattern after
aortic unclamping. Notably, a systemic endotoxemia
A
B C
Fig 3. Mean pulmonary artery pressure (A), cardiac index (B), and systemic vascular index (SVRI) (C) in CPB
patients with either poor APC generation response (PR, n = 8) or good APC generation response (GR, n = 11).
PR and GR groups were defined as APC/protein C antigen ratio less than or greater than 1.5, respectively, in the
plasma sample collected from the coronary sinus 10 minutes after reperfusion. In time of measurement Pre indi-
cates preoperative, Post, immediately post-CPB, CS, during closure of the sternum, and 6 and 24 indicate 6 and
24 hours after operation, respectively. The comparisons between the PR and GR groups were done with the 2-
tailed Student t test for independent samples. *P < .05. The error bars indicate standard error of the mean.
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after aortic unclamping occurred within minutes after
reperfusion of the heart,28,29 indicating that if APC was
formed within the splanchnic circulation, it also could
appear in arterial blood rapidly after aortic unclamping.
Thus protein C activation after aortic unclamping may
represent a general tissue response to reperfusion. 
We were unable to show local activation of protein C
across the coronary circulation as previously suggested
by Snow and associates,13 who used a porcine model of
brief occlusion of the left anterior descending coronary
artery. However, such local activation could not be
excluded because the reperfused coronary vascular bed
could be a site of both enhanced APC consumption and
APC production. The transcoronary gradient of FPA
showed locally enhanced activation of coagulation,
which physiologically may result in consumption of
physiologic anticoagulants including APC. Overall,
however, increased levels of APC were present both
systemically and locally in the coronary circulation on
reperfusion of ischemic tissue. 
In pigs, occlusion of a coronary artery caused a rapid
increase in the APC level in the interventricular vein,
and blocking this activation by anti–protein C mono-
clonal antibodies impaired the recovery of the ischemic
myocardium.13 Additionally, APC reduced arterial
thrombus formation in a variety of animal models.14-19
Thus it is interesting that a low APC generation
response in the present study was associated with com-
promised postoperative recovery of the myocardium
and the hemodynamic state of the patient. Remarkably,
24 hours after the operation, cardiac output, central
venous pressure, and pulmonary artery pressure corre-
lated positively and systemic vascular resistance nega-
tively with APC generation during the immediate
reperfusion of the heart. Qualitatively, these findings in
patients subjected to CPB are in good agreement with
previous porcine data13 and may be explained by
microvascular thrombosis in the coronary or other vas-
cular beds of the body. 
APC and FPA levels correlated directly with each
other, indicating the known significance of thrombin for
activation of protein C.15,27 Thus one might ask whether
the current hemodynamic effects attributed to APC
could actually be mediated by thrombin or by some
other thrombin effect independent of APC, for example,
activation of fibrinolysis. In this regard the current data
are inconclusive because only protein C activation was
measured. However, a causal contribution from APC is
suggested because another direct product of thrombin’s
action, namely the FPA level during reperfusion, did not
significantly correlate with cardiac output, cardiac
index, systemic vascular resistance index, or central
venous pressure (data not shown). 
In summary, the antithrombotic protein C pathway
was activated during reperfusion after CPB, and low
APC formation measured after 10 minutes of reperfu-
sion was associated with decreased myocardial func-
tion 24 hours after operation. Thus a rapid increase in
APC levels during reperfusion of the heart and other
ischemic vascular beds may be an important physio-
logic antithrombotic defense mechanism against
ischemic tissue injury. 
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Commentary
A central paradox of controlling coagulation in the
patient undergoing thoracotomy and cardiopulmonary
bypass (CPB) emerges as the cardiac surgeon strives to
achieve blood fluidity within the CPB circuit and the
patient’s vasculature, as well as an effective procoagu-
lant response to ensure protective hemostasis in the
wound (Fig 1). Heparin, the gold standard for CPB,
inhibits the coagulation mechanism at multiple levels,
especially in the final common pathway, thereby block-
ing in parallel the intravascular and extravascular pro-
coagulant responses. However, the properties of
heparin allowing it to so effectively target the final
common pathway of coagulation underlie its potential
causation of excessive bleeding in hemostatically com-
promised patients.
The properties of thrombin emphasize the biologic
complexity and dichotomous nature of the coagulation
mechanism when it is integrated into the context of host
response effector mechanisms. Thrombin activates cel-
lular elements through cleavage of protease-activated
receptors; short-term consequences of this mechanism
include activation of platelets, and longer-term implica-
tions of protease-activated receptor stimulation may
include changes in vascular smooth muscle cell proper-
ties underlying restenotic and other vascular lesions.1
As a procoagulant enzyme per se, thrombin magnifies
and modulates its biologic effects in a dichotomous
fashion; thrombin activation of factor XI provides a pos-
itive feedback mechanism reinforcing the generation of
procoagulants through the intrinsic system.2 Thrombin
also stimulates the thrombin activatable fibrinolysis
inhibitor, thus diminishing the efficacy of clot lysis.3
In contrast to the above procoagulant effects of
thrombin, after binding to the endothelial cofactor
thrombomodulin, this enzyme also cleaves the plasma
zymogen protein C, resulting in formation of activated
protein C (APC).4 APC is the key enzyme in the
endogenous antithrombotic protein C–protein S (the
latter a cofactor for APC) mechanism, which damps
the final common pathway by proteolytically inacti-
vating factors Va and VIIIa. APC also appears to have
other vasculoprotective effects resulting from its inter-
action with plasminogen activator inhibitor-1 and by
mechanisms yet to be fully characterized. In the latter
context, APC affords protection against a lethal dose
of intravenous Escherichia coli, and, in models of
myocardial ischemia, APC appears to limit tissue
injury by effects that may extend beyond its coagulant
properties.4 The importance of the protein C–protein S
pathway as a natural anticoagulant mechanism is
emphasized by the prothrombotic diathesis observed
in patients with significant functional deficiency of
either plasma protein.4
On the basis of this discussion, formation of APC is
expected when thrombin is generated. In the current
issue of the Journal (see page 422), Petäjä and col-
leagues report that APC is generated during CPB and
coronary reperfusion. Enhanced APC formation during
the immediate reperfusion period is not unexpected.
Restoration of blood flow delivers both key substrates
for energetic metabolism and effector mechanisms
capable of inflicting vascular damage, such as polymor-
phonuclear leukocytes, complement, and coagulation
components to systemic cardiac vasculature. The net
result is increased generation of thrombin, causing both
cleavage of fibrinogen with release of fibrinopeptide A
(Fig 2 in Petäjä and colleagues) and increased APC for-
mation (Fig 1, C and D in Petäjä and colleagues).
Furthermore, that patients who demonstrate more
robust formation of APC (“good responders”) are those
with enhanced hemodynamic performance (Fig 3 in
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Petäjä and colleagues) is also not unexpected because
effective reperfusion will generate both a procoagulant
(production of fibrinopeptide A) and anticoagulant (pro-
duction of APC) response. However, there is the intrigu-
ing possibility that APC may be doing more than sim-
ply reflecting hemodynamic status, based on its
vasculoprotective effect in animal models of ischemia.
This is an area for future study that may reveal yet
another example of the interdependence of the coagula-
tion mechanism and cardiovascular function.
How can we integrate these findings into a broader
understanding of the role of the coagulation mecha-
nism in CPB procedures?
1. Local (wound) and CPB-induced activation of
coagulation during thoracotomy/CPB trigger is un-
avoidable (thus anticoagulant therapy is required) and
is integral to the protective response mounted to inva-
sion of the extravascular and intravascular spaces. An
important component of this procoagulant response is
the triggering of endogenous antithrombotic mecha-
nisms, such as activation of formation of APC. Thus
more selective antithrombotic therapy administered to
patients during CPB/reperfusion, with the goal of spar-
ing natural anticoagulant mechanisms, might be
expected to buttress vascular protective pathways.
2. Nonspecific inhibition of the coagulation mecha-
nism by an agent such as heparin is also more likely to
damp natural antithrombotic mechanisms tied to the
Fig 1. Schematic depiction of the procoagulant response to thoracotomy/cardiopulmonary bypass (CPB). TAFI,
Thrombin-activatable fibrinolysis inhibitor; APC, activated protein C; TF, tissue factor.
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procoagulant pathway, such as the protein C–protein S
mechanism.
3. From a general perspective of prothrombotic
mechanisms operative in thoracotomy/CPB (Fig 1),
more selective control of coagulation might be
achieved by damping effects of the intrinsic system
without critically interfering with extravascular clot-
ting. In this regard, targeting factor IX/IXa would
inhibit both activation of the intrinsic system by the
CPB tubing, as well as tissue factor–dependent, mono-
cyte-mediated mechanisms in the CPB circuit (where
low levels of tissue factor favor activation of factor IX
over that of factor X)5 and has been shown to be effec-
tive in canine and baboon models.6,7 Such a selective
anticoagulant approach would be expected to more
minimally affect the generation of natural antithrom-
botics, such as the protein C pathway.
The coagulation pathway is an integral part of the
host response to surgical procedures, and events that
begin as an apparently simple response to stem local
blood loss can actually have wide-ranging implications
as locally formed thrombin modulates cellular proper-
ties (including direct effects on the vasculature), acti-
vates protein C, and exerts a range of other effects as
well. Selective damping of the procoagulant mecha-
nism to limit intravascular coagulation during surgery
will undoubtedly be the future direction of anticoagu-
lant therapy. The goal of such therapy will be to main-
tain extravascular hemostasis and allow natural
antithrombotic mechanisms, such as formation of APC,
to occur with minimum inhibition while preventing
thrombosis in the CPB circuit and vasculature.
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